However , patients in the dacomitinib group had longer progression-free survival than those in the placebo group ( median 266 months [ 191-332 ] vs 138 months [ 099-174 ] , respectively ; HR 066 [ 95 % CI 055-079 ] ; p < 00001 ) , and a significantly greater proportion of patients in the dacomitinb group achieved an objective response than in the placebo group ( 34 [ 7 % ] of 480 patients vs three [ 1 % ] of 240 patients , respectively ; p = 0001 ) .